NRAS and uterine cancer: NRAS mutations have been mainly described in melanomas and leukemias and their prognostic significance has been unclear, with some data suggesting an association between mutant NRAS and a worse prognosis in melanoma.[40], [41], [42] In our study, there was a high prevalence of NRAS mutations in melanoma (44%), and uterine cancer (15%).